TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Polyrizon Ltd. ( (PLRZ) ) is now available.
On December 3, 2025, Polyrizon Ltd. announced positive preclinical results for its intranasal naloxone hydrogel, which demonstrated superior mucoadhesion compared to an existing marketed product. This advancement suggests potential for more reliable opioid overdose reversal in emergencies, reinforcing the company’s position in the biotechnology sector and highlighting the efficacy of its T&T hydrogel platform.
More about Polyrizon Ltd.
Polyrizon Ltd. is a biotechnology company specializing in the development of innovative intranasal products, particularly focusing on hydrogels that form a protective barrier in the nasal cavity. Their proprietary technologies, including Capture and Contain (C&C) and Trap and Target (T&T), are aimed at enhancing drug delivery and providing protection against viruses and allergens.
Average Trading Volume: 2,553,359
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.32M
See more insights into PLRZ stock on TipRanks’ Stock Analysis page.